Clinical trials of published PIKFYVE inhibitors are underway in the treatment of SARS-CoV-2 and other RNA virus infections [121], as well as amyotrophic lateral sclerosis (ALS) [112,122] and other neurological diseases [41]. Here, PIKFYVE is linked to amyotrophic lateral sclerosis.